Drug Trial Radar · NCT02544529
Echothiophate Iodide for the Prevention of Progression of Myopia
Last checked: Nov 19, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jun 1, 2016
Primary completion
Jun 1, 2016
Study completion Jun 1, 2016
Sponsor
- Lead sponsor
- Danbury Eye Physicians & Surgeons, PCAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 9, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Single group
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 9 years, up to 15 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the hypothesis that myopia progression can be slowed or prevented by low dose Echothiophate Iodide.
Conditions
- Myopia
Interventions
Echothiophate Iodide 0.03% Ophthalmic SolutionDrug
one drop to each eye three times per week for 18 weeks
Carboxymethylcellulose Sodium (0.5%)Drug
one drop to each eye three times per week for 18 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cycloplegic RefractionTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Danbury Eye Physicians & Surgeons, PC
Danbury, Connecticut
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.